SCHEMBL3898658

SCHEMBL3898658

CCOC(=O)C(C)N1CCC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
LMNA P02545 2/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
GAA P10253 2/20 0.39
TSHR P16473 2/20 0.37
CASP6 P55212 1/20 0.37
ATM Q13315 1/20 0.37
CTSL P07711 1/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CHRNA1 P02708 1/20 0.36
CHRNG P07510 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28201107 0.96 ALDH1A1 (0.43) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL4089646 0.96 ALDH1A1 (0.43) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL2961890 0.94 ALDH1A1 (0.42) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL6129180 0.91 ALDH1A1 (0.46) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL687466 0.85 SIGMAR1 (0.40) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL3358932 0.82 ALDH1A1 (0.40) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL27793003 0.82 ALDH1A1 (0.41) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL3353702 0.82 ALDH1A1 (0.40) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL2110264 0.82 SIGMAR1 (0.42) ALDH1A1LMNAMAPTHPGDRAB9A
SCHEMBL16496970 0.82 KDM4E (0.46) ALDH1A1LMNAMAPTHPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1521733-B1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR PFIZER PROD INC (US) 2014-08-20 EP disclosed
US-7553877-B2 Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma PFIZER, INC. (US) 2009-06-30 US disclosed
US-7138406-B2 Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders PFIZER, INC. (US) 2006-11-21 US disclosed
US-20060247264-A1 Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma PFIZER INC 2006-11-02 US disclosed
EP-1521733-A1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR Pfizer Products Inc. (US) 2005-04-13 EP disclosed
US-20040138262-A1 Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders PFIZER INC. 2004-07-15 US disclosed
WO-2004005229-A1 MODULATORS OF THE GLUCOCORTICOID RECEPTOR PFIZER PRODUCTS INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060247264-A1 Use of 2-hydroxy-1,2,3,4,4a,9,10,10a-octahydrophenanthrene compounds glucocorticoid receptor agonists to treat certain inflammatory conditions such as arthritis, asthma NR3C1, NR3C2, LTB4R2 ALDH1A1 999/4885LMNA 3426/4885MAPT 4656/4885
US-20040138262-A1 Antiinflammatory agents; antiallergens; vision defects; anticancer agents; gastrointestinal disorders NR3C1, MC2R, FPR1 ALDH1A1 1613/4885LMNA 4247/4885MAPT 4702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.